
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6695302/publications.pdf Version: 2024-02-01



ALD ÃO ÃOK

#	Article	IF	CITATIONS
1	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	13.7	929
2	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	4.0	685
3	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	2.3	229
4	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry, 2019, 18, 173-182.	4.8	127
5	One year outcome in first episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 37-43.	1.8	117
6	Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases. Schizophrenia Research, 2017, 186, 19-28.	1.1	110
7	Sexual dysfunction in patients with schizophrenia on antipsychotic medication. European Psychiatry, 2007, 22, 328-333.	0.1	91
8	Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. International Clinical Psychopharmacology, 2015, 30, 290-295.	0.9	78
9	Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. Journal of Psychiatric Research, 2004, 38, 163-168.	1.5	71
10	Attitudes of psychiatrists toward patients with schizophrenia. Psychiatry and Clinical Neurosciences, 2004, 58, 89-91.	1.0	70
11	Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry and Clinical Neurosciences, 2004, 58, 434-437.	1.0	64
12	The history of childhood trauma among individuals with ultra high risk for psychosis is as common as among patients with firstâ€episode schizophrenia. Microbial Biotechnology, 2013, 7, 414-420.	0.9	60
13	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. European Neuropsychopharmacology, 2019, 29, 947-959.	0.3	60
14	Remission after first-episode schizophrenia: Results of a long-term follow-up. Psychiatry Research, 2011, 189, 33-37.	1.7	51
15	The impact of antistigma education on the attitudes of general practitioners regarding schizophrenia*. Psychiatry and Clinical Neurosciences, 2006, 60, 439-443.	1.0	48
16	Persistent negative symptoms after first episode schizophrenia: A 2-year follow-up study. Schizophrenia Research, 2014, 158, 241-246.	1.1	47
17	Disability in schizophrenia: Clinical correlates and prediction over 1-year follow-up. Psychiatry Research, 2005, 135, 103-111.	1.7	46
18	Clinical variables associated with suicide attempts in schizophrenia before and after the first episode. Psychiatry Research, 2015, 229, 252-256.	1.7	46

#	Article	IF	CITATIONS
19	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. Schizophrenia Bulletin, 2019, 45, 960-965.	2.3	46
20	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. JAMA Psychiatry, 2022, 79, 260.	6.0	44
21	Cognitive deficits in clinical and familial high risk groups for psychosis are common as in first episode schizophrenia. Schizophrenia Research, 2013, 151, 265-269.	1.1	43
22	Obsessive compulsive disorder and symptoms may have different effects on schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 429-433.	2.5	38
23	History of childhood physical trauma is related to cognitive decline in individuals with ultra-high risk for psychosis. Schizophrenia Research, 2015, 169, 199-203.	1.1	37
24	Association of a serotonin receptor 2A gene polymorphism with cognitive functions in patients with schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 704-707.	1.1	34
25	Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia. Psychiatry Research, 2019, 275, 149-154.	1.7	30
26	Validation of Turkish version of brief negative symptom scale. International Journal of Psychiatry in Clinical Practice, 2016, 20, 265-271.	1.2	29
27	Relationship Between Persistent Negative Symptoms and Findings of Neurocognition and Neuroimaging in Schizophrenia. Clinical EEG and Neuroscience, 2018, 49, 27-35.	0.9	28
28	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study. Psychological Medicine, 2020, 50, 1884-1897.	2.7	28
29	Metabolic Effects of Paliperidone Extended Release Versus Oral Olanzapine in Patients With Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 449-457.	0.7	27
30	Evaluation of Incidence and Clinical Features of Antibody-Associated Autoimmune Encephalitis Mimicking Dementia. Behavioural Neurology, 2014, 2014, 1-4.	1.1	25
31	Electroconvulsive Therapy in First-Episode Schizophrenia. Journal of ECT, 2006, 22, 38-42.	0.3	24
32	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	4.1	23
33	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Psychiatry, 2021, 64, e25.	0.1	18
34	Psychometric liability to psychosis and childhood adversities are associated with shorter telomere length: A study on schizophrenia patients, unaffected siblings, and non-clinical controls. Journal of Psychiatric Research, 2019, 111, 169-185.	1.5	17
35	Anticipated discrimination is related to symptom severity, functionality and quality of life in schizophrenia. Psychiatry Research, 2013, 209, 333-339.	1.7	16
36	Deficits in Go and NoGo P3 potentials in patients with schizophrenia. Psychiatry Research, 2017, 254, 126-132.	1.7	16

#	Article	IF	CITATIONS
37	Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study. Nordic Journal of Psychiatry, 2015, 69, 1708-1714.	0.7	14
38	Relationship of obsessive-compulsive symptoms to clinical variables and cognitive functions in in individuals at ultra high risk for psychosis. Psychiatry Research, 2018, 261, 332-337.	1.7	14
39	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine, 2022, 52, 1910-1922.	2.7	14
40	Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings. Schizophrenia Research, 2021, 229, 27-37.	1.1	14
41	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. Frontiers in Psychiatry, 2022, 13, 826465.	1.3	13
42	Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. CNS Drugs, 2016, 30, 997-1006.	2.7	12
43	Lower prepulse inhibition in clinical highâ€risk groups but not in familial risk groups for psychosis compared with healthy controls. Microbial Biotechnology, 2020, 14, 196-202.	0.9	12
44	Obsessive compulsive symptoms are related to lower quality of life in patients with Schizophrenia. International Journal of Psychiatry in Clinical Practice, 2014, 18, 243-247.	1.2	10
45	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. Psychological Medicine, 2022, 52, 1777-1783.	2.7	10
46	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110440.	2.5	10
47	Relationship of negative symptom severity with cognitive symptoms and functioning in subjects at ultraâ€high risk for psychosis. Microbial Biotechnology, 2021, 15, 966-974.	0.9	8
48	Predictors of discontinuation and hospitalization during long-acting injectable antipsychotic treatment in patients with schizophrenia spectrum disorder. International Clinical Psychopharmacology, 2021, 36, 89-96.	0.9	7
49	Formal thought disorder in patients with first-episode schizophrenia: Results of a one-year follow-up study. Psychiatry Research, 2021, 301, 113972.	1.7	7
50	Treatment Guidelines for Patients with Schizophrenia or Psychotic Disorder who are Hospitalized in a Psychiatry Clinic. Journal of Microbiology and Biotechnology, 2014, 24, 276-288.	0.9	6
51	Lack of progressive reduction in P3 amplitude after the first–episode of schizophrenia: A 6-year follow-up study. Psychiatry Research, 2016, 243, 303-311.	1.7	5
52	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. Frontiers in Psychiatry, 2019, 10, 676.	1.3	5
53	Altered Resting State Functional Connectivity and Its Correlation with Cognitive Functions at Ultra High Risk for Psychosis. Psychiatry Research - Neuroimaging, 2022, 321, 111444.	0.9	5
54	Relapse rates following antipsychotic discontinuation in the maintenance phase after first-episode of schizophrenia: Results of a long-term follow-up study. Schizophrenia Research, 2020, 225, 31-38.	1.1	4

#	Article	IF	CITATIONS
55	Higher schizotypy predicts better metabolic profile in unaffected siblings of patients with schizophrenia. Psychopharmacology, 2018, 235, 1029-1039.	1.5	3
56	Reliability and validity of the Turkish version <scp>of comprehensive</scp> assessment of at risk mental states. Microbial Biotechnology, 2021, 15, 1028-1032.	0.9	3
57	Factors Associated with Dropout and Noncompliance in Patients with Schizophrenia: Results of a One-Year Follow-Up. Clinical Schizophrenia and Related Psychoses, 2007, 1, 161-167.	1.4	3
58	Antistigma Efforts in Turkey: The Turkish Program Against Stigmatization and Discrimination Because of Schizophrenia as a Part of the World Psychiatric Association Global Program. International Journal of Mental Health, 2007, 36, 58-65.	0.5	2
59	Menstrual Cycle-Related Changes in Women with Schizophrenia: A Resting-State fMRI Study. Neuropsychobiology, 2022, , 1-15.	0.9	2
60	Validation of the Turkish version of the self-evaluation of negative symptoms scale (SNS). International Journal of Psychiatry in Clinical Practice, 2022, 26, 221-227.	1.2	2
61	Electrophysiological and Neuroimaging Research on Negative Symptoms: Future Challenges. Clinical EEG and Neuroscience, 2018, 49, 3-5.	0.9	1
62	Treatment principles of first-episode psychosis. Noropsikiyatri Arsivi, 2021, 58, S12-S16.	0.2	1
63	Measuring discrimination experienced by people with a mental illness: replication of the short-form DISCUS in six world regions. Psychological Medicine, 2023, 53, 3963-3973.	2.7	1
64	Other people stigmatize…but, What about us? Attitudes of Mental Health Professionals towards Patients with Schizophrenia. , 0, , 147-159.		1
65	S105. RELATIONSHIP BETWEEN FORMAL THOUGHT DISORDER, AND FUNCTIONING IN INDIVIDUALS WITH ULTRA HIGH RISK FOR PSYCHOSIS. Schizophrenia Bulletin, 2019, 45, S347-S347.	2.3	0
66	M209. TO WHOM WE PRESCRIBE LONG ACTING ANTPSYCHOTICS AT DISCHARGE FROM HOSPITAL?. Schizophrenia Bulletin, 2020, 46, S216-S216.	2.3	0